Entering text into the input field will update the search result below

Opko hits enrollment target in late stage study of hGH-CTP in growth hormone deficient adults

Jul. 10, 2015 9:44 AM ETOPKO Health, Inc. (OPK) StockOPKBy: Douglas W. House, SA News Editor2 Comments
  • Opko Health (OPK +0.2%) completes enrollment in the pivotal Phase 3 clinical trial assessing its long-acting human growth hormone (hGH-CTP) in growth hormone deficient adults. The treatment period in the randomized, double-blind, placebo-controlled study is 26 weeks followed by a 26-week open-label extension.
  • The primary endpoint is the change in trunk fat mass, expressed in kilograms, from baseline to week 26 versus placebo. The projected study completion date is June 2016. If successful, a regulatory submission will follow.
  • The value proposition of hGH-CTP is the reduction of injections, from once daily to once weekly.

Recommended For You

About OPK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
OPK--
OPKO Health, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.